S12 Ep1: FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD

OncLive® On Air - A podcast by OncLive® On Air

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

Dr Schram discusses the significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.